Boehringer Ingelheim’s Kenya Program Transforms Chronic Disease Care for Thousands
Boehringer Ingelheim’s Kenya Program Transforms Chronic Disease Care for Thousands
Boehringer Ingelheim’s Kenya Program Transforms Chronic Disease Care for Thousands
Boehringer Ingelheim has expanded access to healthcare in Kenya through its Access to Healthcare (ATH) program. The initiative targets non-communicable diseases (NCDs) like hypertension and type 2 diabetes, which cause 18 million premature deaths yearly in low- and middle-income countries. Partnering with Zuri Health, MEDS, and Ampath, the company aims to transform treatment for thousands of patients across the country.
The ATH program operates as a core part of Boehringer Ingelheim’s business, aligning with its goal of improving lives for future generations. It follows a patient-centred approach, offering screening, physician assessments, follow-ups, and medication refills. After two years, the scheme has enrolled over 8,000 patients, partnered with more than 30 healthcare centres, and engaged over 345 referring physicians.
A recent Patient Graduation Assessment revealed strong results: 81% of participants showed good knowledge of symptom recognition, disease management, and emergency responses. Patients also shared positive feedback, highlighting how the program changed their treatment experience and health outlook. Many suggested adding in-person support and peer groups to further enhance care. The initiative is part of Boehringer Ingelheim’s broader Sustainable Development for Generations framework. By 2030, the company plans to reach 50 million people worldwide through expanded healthcare access. In Kenya, the focus remains on overcoming common barriers—financial struggles, long travel distances, and daily hardships—that make managing chronic illnesses difficult. Building patient-focused healthcare systems is key to better outcomes. The ATH program demonstrates how structured support can create lasting improvements for individuals and communities alike.
The ATH program has already made measurable progress in Kenya, with thousands of patients now better equipped to manage their conditions. As part of a long-term strategy, Boehringer Ingelheim continues to work toward its 2030 target of helping 50 million people access essential healthcare services. The model’s success in Kenya could serve as a blueprint for similar efforts in other low- and middle-income regions.